Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Ipsen

Status: Completed

Conditions: Renal Cell Carcinoma Metastatic; Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03699579

A-TW-60000-022

Details and patient eligibility

About

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with confirmed diagnosis of clear-cell renal cell carcinoma
• Patients with evidence of metastatic disease
• Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
• Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease

Exclusion criteria

• Patients enrolled in any clinical trial involving anti-cancer therapy
• Pregnant woman